WALTHAM, MA (December 8, 2012): 

NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease. More>>>

PRINCETON, NJ and WALTHAM, MA (October 21, 2009) – BioWa, Inc. (BioWa)

and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement
which provides NKTT with access to BioWa’s patented POTELLIGENT® Technology platform for
the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. More>>>

GENEVA, SWITZERLAND (September 1, 2009): Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today thatthey have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M™. More>>>